Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities

International Journal of Clinical Practice

Volumn 69, Issue 7, 2015, Pages 766-770

  Saltoglu, N ^a   Karali, R ^a   Yemisen, M ^a   Ozaras, R ^a   Balkan, I I ^a   Mete, B ^a   Tabak, F ^a   Mert, A ^a   Hondur, N ^a   Ozturk, R ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAM; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; FOSFOMYCIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TRIMETHOPRIM SULFAMETHOXAZOLE TRIMOXAZOLE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; ASYMPTOMATIC BACTERIURIA; BLADDER CATHETERIZATION; COMMUNITY ONSET HEALTHCARE ASSOCIATED URINARY TRACT INFECTION; COMPARATIVE STUDY; COMPLICATED CYSTITIS; CONTROLLED STUDY; CYSTITIS; DIABETES MELLITUS; DRUG SUBSTITUTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HOSPITAL ACQUIRED URINARY TRACT INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON UROLOGIC NEOPLASM; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PYELONEPHRITIS; RETROSPECTIVE STUDY; SEPSIS; URINARY TRACT INFECTION; URINARY TRACT MALFORMATION; URINARY TRACT TUMOR; URINE CULTURE; UROLITHIASIS; UROLOGIC SURGERY; UROSEPSIS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOLLOW UP; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SECRETION (PROCESS); TIME FACTOR; TURKEY; URINARY TRACT INFECTIONS;

AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; TIME FACTORS; TURKEY; URINARY TRACT INFECTIONS;

EID: 84933280116     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12608     Document Type: Article

References (33)

1. Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R,. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis 2011; 70: 507-11.
2. Auer S, Wojna A, Hell M,. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2010; 54: 4006-8.
3. Jacobsen SM, Stickler DJ, Mobley HLT, Shirliff ME,. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev 2008; 21: 26-59.
4. Nicolle LE, Strausbaugh LJ, Garibaldi RA,. Infections and antibiotic resistance in nursing homes. Clin Microbiol Rev 1996; 9: 1-17.
5. Livermore DM, Canton R, Gniadkowski M, et al., CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
6. Hsueh PR, Lau YJ, Ko WC, et al., Consensus statement on the role of fluoroquinolones in the management of urinary tract infections. J Microbiol Immunol Infect 2011; 44: 79-82.
7. Bradford PA,. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
8. Chaudhary U, Aggrawal R,. Extended-spectrum lactamases (ESBL)-an emerging threat to clinical therapeutics. Indian J Med Microbiol 2004; 22: 75-80.
9. Paterson DL,. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med 2006; 119 (Suppl.): 20-8.
10. Turner PJ,. Extended-spectrum beta-lactamases. Clin Infect Dis 2005; 41 (Suppl.): 273-5.
11. Rodríguez-Baño J, Navarro MD, Romero L, et al., Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43: 1407-14.
12. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Sixteenth informational supplement.Approved standard M100-S19). Wayne, PA: CLSI, 2009.
13. Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB,. Community-onset urinary tract infections: a population-based assessment. Infection 2007; 35 (3): 150-3.
14. CDC, The National Healthcare Safety Network (NHSN). http://www.cdc.gov/nhsn/PDFs/pscManual/psc Manual-current.pdf 2009; 7.1-7.5 (accessed December 16, 2012).
15. Rodríguez-Baño J, Alcalá JC, Cisneros JM, et al., Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168: 1897-902.
16. Ena J, Arjona F, Martínez-Peinado C, Lõpez-Perezagua Mdel M, Amador C,. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology 2006; 68: 1169-74.
17. Buehlmann M, Bruderer T, Frei R, Widmer AF,. Effectiveness of a new decolonisation regimen for eradication of extended-spectrum β-lactamase-producing Enterobacteriaceae. J Hosp Infect 2011; 77: 113-7.
18. Pitout JD, Laupland KB,. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 59-166.
19. Harris AD, McGregor JC, Johnson JA, et al., Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 2007; 13: 1144-9.
20. Skippen I, Shemko M, Turton J, Kaufmann ME, Palmer C, Shetty N,. Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London. J Hosp Infect 2006; 64: 115-23.
21. Martínez JA, Aguilar J, Almela M, et al., Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother 2006; 58: 1082-5.
22. Rodríguez-Baño J, Navarro MD, Romero L, et al., Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in non-hospitalized patients. J Clin Microbiol 2004; 42: 1089-94.
23. Peña C, Gudiol C, Tubau F, et al., Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect 2006; 12: 279-84.
24. Alhambra A, Cuadros JA, Cacho J, Gõmez-Garcés JL, Alõs J,. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother 2004; 53: 1090-4.
25. Rodríguez-Baño J, Navarro MD, Romero L, et al., Clinical and molecular epidemiology of extended-spectrum beta-lactamase producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006; 42: 37-45.
26. Eshwarappa M, Dosegowda R, Aprameya IV, Khan MW, Kumar PS, Kempegowda P,. Clinico-microbiological profile of urinary tract infection in south India. Indian J Nephrol 2011; 21: 30-6.
27. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E,. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med 2005; 165: 1375-80.
28. Paterson DL, Ko WC, Von Gottberg A, et al., Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.
29. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO,. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33: 1288-94.
30. Azap OK, Arslan H, Serefhanoʇlu K, et al., Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010; 16: 147-51.
31. Garau J,. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008; 14 (Suppl.): 198-202.
32. Schito GC, Naber KG, Botto H, et al., The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34: 407-13.
33. Mody RM, Erwin DP, Summers AM, et al., Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms. Ann Clin Microbiol Antimicrob 2007; 6: 6.